Patents by Inventor Sheila Gujrathi

Sheila Gujrathi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240425582
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: September 9, 2024
    Publication date: December 26, 2024
    Applicant: AbbVie, Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Patent number: 12129294
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: October 29, 2024
    Assignee: AbbVie Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Patent number: 12122826
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: October 22, 2024
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Publication number: 20230220061
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: February 3, 2023
    Publication date: July 13, 2023
    Applicant: AbbVie Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Publication number: 20220281968
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: September 8, 2022
    Applicant: AbbVie Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Patent number: 11390669
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: July 19, 2022
    Assignee: Abbvie, Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Publication number: 20210380674
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: April 27, 2017
    Publication date: December 9, 2021
    Applicant: AbbVie Inc.
    Inventors: Gregg TIMONY, Sheila GUJRATHI, Robert PEACH, Allan OLSON
  • Publication number: 20060233797
    Abstract: The present invention concerns treatment of IBD, especially ulcerative colitis (UC), with an antibody that binds to CD20.
    Type: Application
    Filed: April 13, 2006
    Publication date: October 19, 2006
    Inventor: Sheila Gujrathi